omeprazole has been researched along with Kidney Failure in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of lansoprazole (L) after a single oral dose of 30 mg was determined in 18 healthy volunteers, 17 renal failure patients and 24 hepatic failure patients; 8 hepatitis and 16 with compensated (CC) or uncompensated (UCC) cirrhosis." | 3.68 | Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. ( Delhotal-Landes, B; Dellatolas, F; Duchier, J; Flouvat, B; Lemaire, M; Molinie, P, 1993) |
| "Rabeprazole was well tolerated by both groups." | 2.69 | Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. ( Grimes, I; Humphries, TJ; Keane, WF; Swan, SK, 1999) |
| " Mean plasma elimination half-life (t1/2) is between 1." | 2.39 | Clinical pharmacokinetics of lansoprazole. ( Flouvat, B; Landes, BD; Petite, JP, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landes, BD | 1 |
| Petite, JP | 1 |
| Flouvat, B | 2 |
| Delhotal-Landes, B | 1 |
| Duchier, J | 1 |
| Molinie, P | 1 |
| Dellatolas, F | 1 |
| Lemaire, M | 1 |
| Keane, WF | 1 |
| Swan, SK | 1 |
| Grimes, I | 1 |
| Humphries, TJ | 1 |
1 review available for omeprazole and Kidney Failure
| Article | Year |
|---|---|
Clinical pharmacokinetics of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aging; Anti-Ulcer Agents; Drug Interactions; Gastrointestin | 1995 |
1 trial available for omeprazole and Kidney Failure
| Article | Year |
|---|---|
Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Blood Cells; Blood Chemical Analysis | 1999 |
1 other study available for omeprazole and Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Administration, Oral; Adult; Aged; Female; Half | 1993 |